Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Diet and exercise may tame hormone Therapy's metabolic side effects in prostate cancer

NCT ID NCT04870515

First seen Jan 09, 2026 · Last updated Jun 22, 2026 · Updated 24 times

Summary

This pilot study tested whether a diet and exercise program could prevent or reduce metabolic side effects like insulin resistance and weight gain in 20 men with prostate cancer receiving hormone therapy and radiation. Participants followed dietary instructions and did aerobic and strength exercises. The study measured changes in insulin resistance, body weight, waist size, and body composition.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

dietary and exercise intervention

What this could lead to

If successful, this approach could help manage weight and insulin resistance caused by hormone therapy, improving quality of life for prostate cancer patients.

What could go wrong

This is a very small pilot study with only 20 participants, so results may not apply to everyone. The intervention requires significant lifestyle changes, which may be hard to maintain.

Conditions

The condition(s) this trial relates to.

prostate adenocarcinoma prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.